Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study hypothesizes that the sulfonamide group in tamsulosin might contribute to its association with intraoperative floppy iris syndrome.

This case report presents the first instance in Korea of unilateral gynecomastia and breast pain associated with doxazosin use.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.

This review discusses the drug treatment of benign prostatic syndrome, highlighting the efficacy of combination therapies over monotherapies in patients at high risk for disease progression, but notes increased side effects and costs.

This study found that higher baseline expression of SRD5A2 in prostate tissue was associated with a better response to finasteride in men with benign prostatic hyperplasia.

This study found that tamsulosin, finasteride use, and aging are significantly associated with increased risk of intraoperative floppy iris syndrome during cataract surgery, while doxazosin does not appear to pose this risk.

This review discusses the effectiveness and tolerability of alpha1-adrenoceptor antagonists for managing lower urinary tract symptoms in benign prostatic hyperplasia, reporting no new clinical results.

This review discusses various treatments for benign prostatic hyperplasia, comparing medications like finasteride and terazosin, as well as surgical and placebo options, without presenting new clinical findings.

This study concluded that male patients with improved lower urinary tract symptoms may have a lower risk of death, suggesting a potential benefit of treating symptoms beyond just managing patient discomfort.

This article discusses the use of direct vasodilators and sympatholytic agents in hypertension management, highlighting their utility in specific cases like refractory hypertension and heart failure, but reports no new clinical results.

This study identified distinct and significant adverse event patterns across different drug classes used to treat benign prostatic hyperplasia, confirming known risks and suggesting novel safety signals for further investigation.

This study analyzed the FDA Adverse Event Reporting System and found distinct safety signals and adverse event patterns among α1-blockers, 5α-reductase inhibitors, and tadalafil used in treating benign prostatic hyperplasia, emphasizing known risks and identifying potential new ones that require further study.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

This article reports a case of pseudofolliculitis barbae potentially induced by the use of oral minoxidil.

This review discusses medical treatments for lower urinary tract symptoms suggestive of benign prostatic hyperplasia, focusing on their effects, side-effects, and implications for treatment goals, but reports no new clinical results.

This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.

In this study, D-004 did not affect androgen-dependent development in rats exposed in utero, while finasteride caused significant changes in male offspring's androgen-dependent tissues.

This study evaluated a menthol-based microemulsion for transdermal delivery of finasteride and silodosin, finding that it enhanced skin permeation and flux compared to aqueous solutions, suggesting a promising method for managing benign prostatic hyperplasia.

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

Finasteride can cause enlarged breasts.

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

This case report describes a 60-year-old postmenopausal woman with virilization and hirsutism caused by hilus-cell hyperplasia, which was confirmed following bilateral salpingo-oophorectomy.

This study examined the dementia risk in patients with benign prostatic hyperplasia using alpha-blockers and 5-alpha reductase inhibitors, finding no significant association between these medications and increased dementia risk compared to no treatment, but noted higher risk probabilities for certain 5ARIs.

This case report highlights a rare instance of minoxidil-induced pleuro-pericardial effusion with tamponade in a patient with end-stage renal disease on hemodialysis, which improved following pericardiocentesis and discontinuation of the drug.

This case report describes a 90-year-old man diagnosed with wild-type transthyretin cardiac amyloidosis, confirmed by pyrophosphate cardiac scintigraphy and exclusion of gene mutations.

This article discusses the coexistence of amyloidosis and aortic stenosis in elderly patients and explores potential therapeutic strategies, without reporting new clinical results.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

Dutasteride, fesoterodine, and finasteride help older patients with urinary issues.

This study found that Caesalpinia bonduc seed extracts significantly reduced prostate weight and improved prostate tissue morphology in Wistar rats with testosterone-induced benign prostatic hyperplasia.